Laffan, M
~ 400  Ergebnisse:
Personensuche X
?
1

OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After ..:

Mahlangu, J. ; von Drygalski, A. ; Shapiro, S....
Research and Practice in Thrombosis and Haemostasis.  7 (2023)  - p. 100459 , 2023
 
?
2

PB1370 Thrombocytosis and Acquired Bleeding Disorders in Pa..:

Simini, G. ; Vinayagam, S. ; Karawitage, N....
Research and Practice in Thrombosis and Haemostasis.  7 (2023)  - p. 101503 , 2023
 
?
3

PB0511 Safety and Efficacy of Therapeutic Anticoagulation w..:

Simini, G. ; Akor, F. ; Krishnamoorthi, A....
Research and Practice in Thrombosis and Haemostasis.  7 (2023)  - p. 101873 , 2023
 
?
5

A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERA..:

Ozelo, M.C. ; Pasi, K.J. ; Rangarajan, S....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 60 , 2020
 
?
 
?
7

Can you grow out of von Willebrand disease?:

Laffan, M.
Haemophilia.  23 (2017)  6 - p. 807-809 , 2017
 
?
8

ADAMTS-13 glycans and conformation-dependent activity:

Nowak, A. A. ; O'Brien, H. E. R. ; Henne, P....
Journal of Thrombosis and Haemostasis.  15 (2017)  6 - p. 1155-1166 , 2017
 
?
10

Thromboelastography (TEG®) demonstrates that tinzaparin 450..:

Griffiths, S. ; Woo, C. ; Mansoubi, V....
International Journal of Obstetric Anesthesia.  29 (2017)  - p. 50-56 , 2017
 
?
11

Von Willebrand factor and angiogenesis: basic and applied i..:

Randi, A. M. ; Laffan, M. A.
Journal of Thrombosis and Haemostasis.  15 (2017)  1 - p. 13-20 , 2017
 
?
 
?
14

Site-specific analysis of von Willebrand factorO-glycosylat..:

Solecka, B. A. ; Weise, C. ; Laffan, M. A..
Journal of Thrombosis and Haemostasis.  14 (2016)  4 - p. 733-746 , 2016
 
?
15

International Society on Thrombosis and Haemostasis core cu..:

McLintock, C. ; Pabinger, I. ; Bauer, K. A....
Journal of Thrombosis and Haemostasis.  14 (2016)  1 - p. 3-27 , 2016
 
1-15